Galena Biopharma, Inc. (SLS)

Last Closing Price: 1.63 (2025-06-05)

Company Description

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $1.00M
Net Income (Most Recent Fiscal Year) $-30.88M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 5.55
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -193.67%
Return on Assets (Trailing 12 Months) -113.02%
Current Ratio (Most Recent Fiscal Quarter) 4.64
Quick Ratio (Most Recent Fiscal Quarter) 4.64
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $0.13
Earnings per Share (Most Recent Fiscal Quarter) $-0.07
Earnings per Share (Most Recent Fiscal Year) $-0.50
Diluted Earnings per Share (Trailing 12 Months) $-0.38
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 99.78M
Free Float 98.38M
Market Capitalization $162.64M
Average Volume (Last 20 Days) 2.80M
Beta (Past 60 Months) 2.25
Percentage Held By Insiders (Latest Annual Proxy Report) 1.40%
Percentage Held By Institutions (Latest 13F Reports) 17.38%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%